Evaluation of the The Neuromodulation System for the Treatment of Overactive Bladder Symptoms

Overactive Bladder Clinical Trial

Official title:

A Prospective, Multi-center, Randomized Controlled, Double-blind, Superiority Clinical Trial Evaluating the Safety and Efficacy of a Non-invasive Low-frequency Tibial Nerve Stimulator for the Treatment of Overactive Bladder

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04999657
• Other study ID #: EMK03025P
• Status: Completed
• Phase: N/A
• Start date: August 26, 2021
• Est. completion date: December 15, 2022

Study information

• Verified date: January 2023
• Source: Medtecx Co Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of non-invasive tibial nerve stimulator for the treatment of overactive bladder under the premise of ensuring the safety of the subjects and ensuring the scientific nature of the clinical trial. The primary safety endpoint will be device-related adverse events. The primary effectiveness endpoint will be the improvement value of overactive bladder symptom score (OABSS) after 12-week treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 109
• Est. completion date: December 15, 2022
• Est. primary completion date: September 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Women and men aged between 18 and 80 years old (including 18 and 80 years old);

2. Individual with primary OAB, or with OAB symptoms, satisfies one of the following conditions: ? Urinary urgency: sudden and strong desire to urinate, and it is difficult to be subjectively suppressed and delayed urination ; ? Urge urinary incontinence: accompanied with urinary urgency or immediately after urinary urgency ; ? Urination frequency: adults urination frequency =8 times during the daytime,=2 times at night, and each urine volume <200 ml .

3. Individual meets the diagnostic criteria of OAB: According to the OABSS questionnaire, urgency score =2 points, total score =3 points, and symptoms duration =3 months;

4. Individual newly diagnosed with OAB have not been medicated, or is able to stop taking OAB-related drugs (M receptor block, ß3 receptor agonists) for at least 2 weeks prior to enrollment;

5. The subject has autonomy and can go to the toilet independently;

6. Individual is ambulatory and able to use the toilet independently;

7. Individual is capable and willing to participate in the study and provide the written informed consent.

Exclusion Criteria:

1. Woman is pregnant or lactating, or woman of childbearing age who plans to become pregnant during the study period;

2. Individual has Stress Urinary Incontinence (SUI);

3. Individual has obvious urinary obstruction due to various reasons accompanied by residual urine volume> 100 ml;

4. Individual has an implanted pacemaker, embedded cardioverter defibrillator, or other electrical medical devices (including sacral neuromodulation (SNM) devices)

5. Individual has uncured urinary system infection;

6. Individual has urinary calculus resulting in lower urinary tract symptoms;

7. Individual has congenital urinary tract malformations causing uncured lower urinary tract symptoms;

8. Individual has uncured cancers;

9. Individual had undergone lower urinary tract surgery within 3 months;

10. Individual has neurological diseases or injuries accompanied with uncured lower urinary tract symptoms;

11. Individual has skin breakage, malignant tumor or acute purulent inflammation on the surface of the plantar where the electrode pads are to be placed;

12. Individual has participated in other drug clinical trials medical dev within 3 months, or participated in other ice clinical trials within 30 days;

13. Individual is deemed unsuitable for enrollment in the study by investigator.

Related Conditions & MeSH terms

• Overactive Bladder
• Urinary Bladder, Overactive

Intervention

Device:
• Non-invasive low-frequency tibial nerve stimulator (TNS-01)
The investigational device is a transcutaneous electrical nerve stimulation (TENS) device that is designed to provide stimulation to the nerves at the site of application via surface electrodes temporarily adhered to the skin.

Locations

Country	Name	City	State
China	Beijing Hospital	Beijing	Beijing
China	West China Hospital	Chengdu
China	Nan Fang Hospital	Guangzhou
China	Zhejiang Provincial People's Hospital	Hangzhou
China	Shanghai Fifth People's Hospital	Shanghai
China	Shanghai General Hospital	Shanghai
China	The First Affiliated Hospital of XI'AN JiaoTong University	Xi'an

Sponsors (1)

Lead Sponsor	Collaborator
Medtecx Co Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The change of overactive bladder symptom score (OABSS) after 12-week treatment compared with baseline	OABSS is evaluated via 3-day voiding diary and urinary voiding events of the previous week at week 0, 4, 8 and 12 after treatment. Evaluate OABSS improvement from baseline after 12 weeks of treatment and compared between the Treatment and the Control groups	12 weeks